The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Abbott Laboratories's revenues will wither -43.7% and EPS will shrink -64.2%.
The average estimate for revenue is $5.52 billion. On the bottom line, the average EPS estimate is $0.44.
Last quarter, Abbott Laboratories recorded revenue of $5.38 billion. GAAP reported sales were 1.8% higher than the prior-year quarter's $5.28 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.42. GAAP EPS of $0.34 for Q1 were 56% lower than the prior-year quarter's $0.78 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 54.8%, 60 basis points worse than the prior-year quarter. Operating margin was 11.4%, 180 basis points better than the prior-year quarter. Net margin was 10.1%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $22.46 billion. The average EPS estimate is $2.01.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,518 members out of 2,610 rating the stock outperform, and 92 members rating it underperform. Among 648 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 633 give Abbott Laboratories a green thumbs-up, and 15 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abbott Laboratories is outperform, with an average price target of $35.37.
Is Abbott Laboratories the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Abbott Laboratories to My Watchlist.